Johnson & Johnson vs Eli Lilly
Johnson & Johnson (JNJ), health care, and Eli Lilly (LLY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Eli Lilly is worth $1.26T on the stock market and Johnson & Johnson $675.5B: Eli Lilly is valued at 86% more. Johnson & Johnson trades at 42.6 times earnings and Eli Lilly at 45.9. Over the past year Johnson & Johnson's share price has moved +41.3% and Eli Lilly's +39.0%.
Key facts
- Johnson & Johnson market value
- $675.5B
- Eli Lilly market value
- $1.26T
- Johnson & Johnson P/E
- 42.6
- Eli Lilly P/E
- 45.9
- Johnson & Johnson revenue
- $94.2BFY to 2025-12-28
- Eli Lilly revenue
- $65.2BFY to 2025-12-31
- Superinvestors holding both
- 12
Market values as of .
| Measure | Johnson & Johnson | Eli Lilly |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-28 | 2025-12-31 |
| Size | ||
| Market cap | $675.5Blower | $1.26Thigher |
| Revenue | $94.2Bhigher | $65.2Blower |
| Earnings | $26.8Bhigher | $20.6Blower |
| Employees | 138,200higher | 50,000lower |
| Total assets | $199.2Bhigher | $112.5Blower |
| Valuation | ||
| P/E | 42.6lower | 45.9higher |
| P/S | 7.2lower | 19.3higher |
| P/B | 8.3lower | 31.3higher |
| Dividend yield | 1.87%higher | 0.47%lower |
| Profitability | ||
| Operating margin | — | — |
| Balance sheet | ||
| Net assets | $81.5Bhigher | $26.5Blower |
| Total liabilities | $117.7Bhigher | $85.9Blower |
| Total debt | $47.9Bhigher | $42.5Blower |
| Cash on hand | $19.7Bhigher | $7.3Blower |
| Price change | ||
| Today | -0.68%higher | -1.22%lower |
| 1 year | +41.3%higher | +39.0%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (12)
- Jeremy Grantham (co-founder)4.0% / 1.9%
- Ken Fisher1.1% / 1.8%
- Mairs & Power team0.9% / 3.4%
- Ray Dalio (founder)0.7% / 0.4%
- Cliff Asness0.3% / 0.4%
- Ken Griffin0.2% / 0.7%
- Mario Gabelli0.2% / 0.3%
- George Soros0.1% / 0.4%
- Jensen team0.1% / 4.0%
- Murray Stahl0.1% / 0.1%
- Rajiv Jain<0.1% / 1.6%
- Dodge & Cox team<0.1% / <0.1%
Johnson & Johnson only (11)
- Tweedy, Browne team4.1%
- Stephen Yacktman4.0%
- Mark Boyar2.6%
- Tom Gayner1.3%
- Fred DiSanto1.1%
- Andrew Spokes0.7%
- Charles Brandes (founder)0.3%
- John Rogers0.1%
- Christopher Bloomstran<0.1%
- Howard Gleicher<0.1%
- Thomas Russo<0.1%
Eli Lilly only (16)
- Primecap team6.5%
- Polen Capital team4.6%
- Larry Robbins1.4%
- Cathie Wood0.7%
- Jeffrey Altman0.6%
- Temasek0.5%
- Brandon Haley0.5%
- David Shaw (founder)0.4%
- Stanley Druckenmiller0.3%
- John Overdeck and David Siegel (founders)0.3%
- Frank Sands0.2%
- Ron Baron0.2%
- Paul Tudor Jones0.2%
- Israel Englander0.1%
- Rob Citrone0.1%
- Bill Nygren<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Johnson & Johnson / Eli Lilly). Who owns JNJ · Who owns LLY
More on Johnson & Johnson
Further comparisons
Johnson & Johnson against its closest peers
Eli Lilly against its closest peers
Learn
Questions and answers
Which is bigger, Johnson & Johnson or Eli Lilly?
By market value, Eli Lilly is the larger: $1.26T against $675.5B for Johnson & Johnson. By revenue in its latest fiscal year, Johnson & Johnson is the larger: $94.2B against $65.2B for Eli Lilly.
Which has the higher P/E ratio?
Eli Lilly: 45.9, against 42.6 for Johnson & Johnson. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher dividend yield?
Johnson & Johnson: 1.87%, against 0.47% for Eli Lilly. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Johnson & Johnson: $47.9B, against $42.5B for Eli Lilly. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Johnson & Johnson and Eli Lilly?
In their latest 13F filings, Jeremy Grantham (co-founder), Ken Fisher, Mairs & Power team, Ray Dalio (founder), Cliff Asness, Ken Griffin, Mario Gabelli, George Soros, Jensen team, Murray Stahl, Rajiv Jain and Dodge & Cox team hold both.
Cite this page
Funkfolio, “Johnson & Johnson vs Eli Lilly”, data as of 17 November 2026. https://funkfolio.com/compare/jnj-vs-lly
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.